Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -135.38% is 82% below its 5-year average of -74.46%, near the low end of its 5-year range (-153.72%–-24.74%).
As of the fiscal period ended Tuesday, June 30, 2026. 9.67% below its 12-month average of -123.45%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -135.38%.
RETURN ON INVESTED CAPITAL (ROIC)
-135.38%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-123.45%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-93.40%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-74.46%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-74.57%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-9.67%
CURRENT VS 3Y AVG
-44.94%
CURRENT VS 5Y AVG
-81.81%
CURRENT VS 10Y AVG
-81.54%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-27.41%
median of 447 covered companies
CURRENT VS SECTOR MEDIAN
-393.90%
vs the sector median at left
Coherus Oncology, Inc.
Market Cap
$173.04M
Return on Invested Capital (ROIC)
-135.38%
TTM Avg
-123.45%
3Y Avg
-93.40%
5Y Avg
-74.46%
Market Cap
$172.99M
Return on Invested Capital (ROIC)
-46.59%
TTM Avg
-39.23%
3Y Avg
-33.74%
5Y Avg
-53.74%
Market Cap
$174.17M
Return on Invested Capital (ROIC)
-30.23%
TTM Avg
-28.70%
3Y Avg
-31.34%
5Y Avg
-41.69%
Market Cap
$176.96M
Return on Invested Capital (ROIC)
-1039.56%
TTM Avg
-137.05%
3Y Avg
-111.74%
5Y Avg
-93.55%
Market Cap
$179.70M
Return on Invested Capital (ROIC)
-9.57%
TTM Avg
-477.38%
3Y Avg
-295.61%
5Y Avg
-295.61%
Market Cap
$162.82M
Return on Invested Capital (ROIC)
-56.53%
TTM Avg
-185.89%
3Y Avg
-125.01%
5Y Avg
-88.85%
Market Cap
$184.12M
Return on Invested Capital (ROIC)
-5.22%
TTM Avg
-22.12%
3Y Avg
-29.09%
5Y Avg
-27.39%
Market Cap
$160.82M
Return on Invested Capital (ROIC)
-13.94%
TTM Avg
-16.11%
3Y Avg
-25.11%
5Y Avg
-17.04%
Market Cap
$153.84M
Return on Invested Capital (ROIC)
-118.67%
TTM Avg
-87.91%
3Y Avg
-55.09%
5Y Avg
-41.64%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | $173.04M | -135.38% | -123.45% | -93.40% | -74.46% |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.99M | -46.59% | -39.23% | -33.74% | -53.74% |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | -30.23% | -28.70% | -31.34% | -41.69% |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | -1039.56% | -137.05% | -111.74% | -93.55% |
| Canton Strategic Holdings Inc (CNTN)vs › | $179.70M | -9.57% | -477.38% | -295.61% | -295.61% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $162.82M | -56.53% | -185.89% | -125.01% | -88.85% |
| Journey Medical Corporation (DERM)vs › | $184.12M | -5.22% | -22.12% | -29.09% | -27.39% |
| Inogen, Inc. (INGN)vs › | $160.82M | -13.94% | -16.11% | -25.11% | -17.04% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $153.84M | -118.67% | -87.91% | -55.09% | -41.64% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | -74.02% | -48.91% | -62.69% | -47.07% |
ROIC
-135.4%
ROE
-215.3%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -135.38% |
| 2026-03-31 | -125.19% |
| 2025-12-31 | -153.72% |
| 2025-09-30 | -122.89% |
| 2025-06-30 | -80.04% |
| 2025-03-31 | -98.75% |
| 2024-12-31 | -82.71% |
| 2024-09-30 | -78.11% |
| 2024-06-30 | -88.20% |
| 2024-03-31 | -50.78% |
| 2023-12-31 | -68.23% |
| 2023-09-30 | -53.30% |
| 2023-06-30 | -76.90% |
| 2023-03-31 | -85.97% |
| 2022-12-31 | -75.08% |
| 2022-09-30 | -64.53% |
| 2022-06-30 | -48.68% |
| 2022-03-31 | -40.36% |
| 2021-12-31 | -51.33% |
| 2021-09-30 | -38.03% |
| 2021-06-30 | -24.74% |
| 2021-03-31 | -9.57% |
| 2020-12-31 | 21.89% |
| 2020-09-30 | 26.85% |
| 2020-06-30 | 31.50% |
| 2020-03-31 | 46.31% |
| 2019-12-31 | 35.50% |
| 2019-09-30 | 0.96% |
| 2019-06-30 | -59.47% |
| 2019-03-31 | -123.69% |
| 2018-12-31 | -308.76% |
| 2018-09-30 | -162.82% |
| 2018-06-30 | -114.39% |
| 2018-03-31 | -200.07% |
| 2017-12-31 | -172.96% |
| 2017-09-30 | -163.67% |
| 2017-06-30 | -86.50% |
| 2017-03-31 | -68.81% |
| 2016-12-31 | -94.94% |
| 2016-09-30 | -70.67% |
| 2016-06-30 | -175.41% |
| 2016-03-31 | -185.03% |
| 2015-12-31 | -205.96% |
| 2015-09-30 | -161.46% |
| 2015-06-30 | -71.62% |
| 2015-03-31 | -86.60% |
| 2014-12-31 | -47.76% |
| 2014-09-30 | -58.28% |
| 2014-06-30 | -61.82% |
